FDA Year-End Drug Approval Showdown: Seven Blockbuster Candidates Face Final Decisions

Dec 15, 2025 14:46 CST Updated 14:46

GSK

Pharmaceutical R&D Manufacturer

Rhythm Pharmaceuticals

Peptide Therapy Developer

Corcept Therapeutics

Drug Developer

Abstract:By the end of 2025, the FDA enters a busy period for new drug approvals.Key rulings on seven major drugs will be made from late December to the end of the year, covering multiple therapeutic areas including asthma, dry eye syndrome, rare obesity, and Cushing's syndrome.Among them, there are GSK's ultra-long-acting antibody冲刺 for double indications, Aldeyra's third attempt at a dry eye drug, and Vanda's controversial drug facing a second round of博弈. This "year-end大考" will reshape the treatment landscape for multiple diseases.

GSK Dual Indications Simultaneous Approval, Semi-Annual Dosing Becomes Core Selling Point

On December 16, the FDA will make the first ruling on GSK's anti-IL-5 antibody depemokimab, which targets both asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).

This ultra-long-acting biologic exerts its anti-inflammatory effects by targeting the IL-5 cytokine, demonstrating impressive results in clinical trials. In the SWIFT-1 and SWIFT-2 trials for asthma, it reduced the annual rate of exacerbations by 48% to 58% compared to placebo; in the ANCHOR-1 and ANCHOR-2 trials for CRSwNP, it significantly improved patients' nasal polyp scores and nasal congestion symptoms. If approved, it will become the first drug of its kind to be administered every six months, greatly enhancing patient convenience.

Aldeyra Makes Third Push, Dry Eye Drug Aims for Comeback with Chamber Test

By December 16, Aldeyra's dry eye disease candidate drug reproxalap will face the FDA’s third review decision. The drug's path to market has been fraught with challenges, as its initial application in 2023 was rejected due to "unproven efficacy for ocular symptoms," and it was again turned down in April 2025, with a request for additional clinical data.

A turning point occurred in June this year when Aldeyra reached an agreement with the FDA, requiring only supplementary chamber trial data for dry eye syndrome to resubmit. The trial eventually succeeded, and in July, the FDA accepted the resubmission. Whether it can achieve "success on the third attempt" has become a focal point of industry attention.

Rare Diseases and Chronic Conditions Make Joint Progress: Multiple Drugs Expand Treatment Boundaries

Before December 20, Rhythm Pharmaceuticals will seek approval for a new indication of Imcivree: "acquired hypothalamic obesity." This rare form of obesity is often triggered by hypothalamic injury or anatomical abnormalities and results from disrupted MC4R signaling, leading to uncontrolled appetite. The Phase III TRANSCEND study demonstrated that the drug reduced patients' BMI by a significant 19.8% compared to placebo.

Imcivree has been approved for multiple rare obesity conditions, and if this expansion succeeds, it will benefit more patients. Before December 30, Corcept Therapeutics' cortisol modulator relacorilant will also face a decision. The drug targets Cushing's syndrome, improving hypercortisolism symptoms by targeting the glucocorticoid receptor, with key trial GRACE and subsequent extension studies providing strong data support.

Vanda's Controversial Drug Approaching Final Verdict, A Year-long Tug-of-war Awaits Outcome

On December 30, Vanda Pharmaceuticals' gastroparesis drug tradipitant will face a second FDA ruling. Following its initial rejection in September last year, the drug sparked a public dispute between the company and the FDA. Vanda accused the FDA of "ignoring evidence," while the FDA responded that its late-stage trial "did not show statistically significant efficacy."

The conflict between the two parties continued to escalate, with Vanda once lodging a complaint with the former FDA director, criticizing the agency for its "lack of transparency in decision-making," until a cooperation framework was reached in October. This ruling will bring an end to the year-long tug-of-war.

Year-End Final Push: Bipolar Depression New Drug Targets High-Risk Population

By the end of 2025, NRx Pharmaceuticals' NRX-101 will be under review for approval, targeting bipolar depression patients at risk of akathisia. As a fixed-dose combination of D-cycloserine and lurasidone, its Phase IIb/III data shows a 33% reduction in suicide risk and a 70% decrease in akathisia symptoms. If approved, it will become the first treatment option specifically for this high-risk patient group.

Reference Source:https://www.biospace.com/fda/fdas-conundrum-what-to-do-with-approved-drugs-that-fail-pivotal-or-confirmatory-trials

Scan the WeChat QR code, add the editor of the Biologics Circle, and those who meet the requirements can join.
Biological Products WeChat Group!
Please indicate: Name + Research Direction!

Edition
Authority
Sound
Bright

All articles reproduced in this official account are intended to convey more information, with the source and author clearly indicated. Media or individuals who do not wish to be reprinted may contact us (cbplib@163.com), and we will immediately proceed with deletion. All articles represent the views of the author and not of this site.